United Health (UNH) Offering Possible 44.93% Return Over the Next 23 Calendar Days

United Health's most recent trend suggests a bearish bias. One trading opportunity on United Health is a Bear Call Spread using a strike $352.50 short call and a strike $357.50 long call offers a potential 44.93% return on risk over the next 23 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $352.50 by expiration. The full premium credit of $1.55 would be kept by the premium seller. The risk of $3.45 would be incurred if the stock rose above the $357.50 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for United Health is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for United Health is bearish.

The RSI indicator is at 48.44 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for United Health

UnitedHealth Group Incorporated (NYSE:UNH) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mon, 25 Jan 2021 05:35:12 +0000
The full-year results for UnitedHealth Group Incorporated ( NYSE:UNH ) were released last week, making it a good time…

Stock Market Rally Powers To Highs As Netflix, Apple Lead Big Tech Rally; Tesla Model Y Launches In China: Weekly Review
Fri, 22 Jan 2021 21:20:09 +0000
The stock market hit new highs, as Netflix surged on subscriber gains, with Apple and other big techs rallying too. Tesla Model Y deliveries began in China.

Healthcare ETFs in Focus on UnitedHealth's Solid Q4 Earnings
Thu, 21 Jan 2021 15:30:03 +0000
UnitedHealth Group (UNH) reported better-than-expected fourth-quarter 2020 results wherein it breezed past the Zacks Consensus Estimate on both earnings and revenues.

UnitedHealth 4Q Sales Top Street Estimates Driven By Optum Business
Thu, 21 Jan 2021 13:11:54 +0000
UnitedHealth Group reported better-than-expected fourth-quarter results despite a spike in pandemic-led healthcare costs. The healthcare giant’s 4Q sales rose 7.5% to $65.5 billion year-on-year, exceeding consensus estimates of $65.1 billion. Shares closed at $350.84 on Jan. 20. UnitedHealth (UNH) posted 4Q adjusted earnings of $2.52 per share, which beat analysts’ estimates of $2.40 per share. The company’s 4Q net EPS (earnings per share) of $2.30 fell from the $3.68 posted during the same quarter last year. Its adjusted EPS of $2.52 per share declined from $3.90 in 4Q19. This decline in earnings per share was largely related to higher healthcare costs due to Covid-19, the company said. For FY20, revenue rose 6% to $257.1 billion year-on-year, led by a 21% uptick in sales at its Optum business. Optum is UnitedHealth’s information technology-enabled health services business that serves different dimensions of the healthcare system including care providers, life sciences companies, and consumers. (See UNH stock analysis on TipRanks) UnitedHealth’s CEO, David S. Wichmann, commented, “We are grateful for the human spirit and resolve of our people, including our 125,000 clinicians who, with other frontline health care workers, demonstrated extraordinary collaboration, compassion and innovation.” The company affirmed its FY21 earnings outlook and expects net earnings of between $16.90 to $17.40 per share and adjusted net earnings of between $17.75 to $18.25 per share. According to UnitedHealth, this outlook includes a negative impact of approximately $1.80 per share due to Covid-19 that included testing and treatment costs and people deferring healthcare in 2020. Following the 4Q results, Oppenheimer analyst Michael Wiederhorn reiterated a Buy rating on the stock and set a price target of $375. “The company’s Optum business is a nice complement to its core managed care operations and continues to account for a large share of earnings,” Wiederhorn commented in a note to investors. Furthermore, UNH’s vertical integration strategy strengthens the company’s competitive positioning across many areas of the healthcare landscape.” Overall, analysts are bullish about the stock and the consensus is a Strong Buy with 16 analysts suggesting a Buy and 2 analysts recommending a Hold. The average price target of $396.44 implies 13% upside potential to current levels. Related News:Aclaris Explodes 220% On ‘Positive Data’ From Rheumatoid Arthritis TrialAkzo Nobel Enters Tikkurila Takeover Battle With $1.7B BidMasterCraft Is Going Digital For Its Dynamic Boat Show Season More recent articles from Smarter Analyst: 2 “Strong Buy” Penny Stocks That Could See Outsized Gains United Airlines Posts Wider-Than Feared Loss of $1.9B In 4Q; Street Says Hold Thursday’s Pre-Market: Here’s What You Need To Know Before The Market Opens Inovio Sinks 7% After Pricing Of $150.5M Share Offering; Street Says Hold

How Many UnitedHealth Group Incorporated (NYSE:UNH) Shares Do Institutions Own?
Thu, 21 Jan 2021 10:26:31 +0000
The big shareholder groups in UnitedHealth Group Incorporated ( NYSE:UNH ) have power over the company. Institutions…

Be Sociable, Share!

Related Posts


MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.